Affiliation:
1. University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Department of Pharmacy Practice Buffalo General Medical Center, Department of Pharmacy
2. The University of Tennessee Health Science Center College of Pharmacy
Abstract
Peripheral arterial disease (PAD) is the third leading cause of atherosclerotic morbidity after coronary heart disease and stroke yet is widely underdiagnosed and undertreated. Treatment of risk factors such as diabetes and cigarette smoking can benefit patients with PAD. Patients should have adequate blood pressure and lipid control to decrease clinical manifestations and symptoms of PAD. Use of antithrombotic medications should be individualized to the patient depending on presence of symptoms, revascularization, and comorbidities. All patient care providers, including physicians, pharmacists, nurse practitioners, and physician assistants should incorporate PAD screening in their at-risk patients to improve access for appropriate earlier diagnosis, initiation of guideline directed therapy, and risk factor modification in order to reduce both major adverse CV and limb outcomes. The purpose of this narrative review is to provide an overview of PAD, summarize clinical trial evidence and guideline recommendations for screening and treatment in order to increase awareness among health care providers to ultimately have a positive impact on patient care.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference81 articles.
1. AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines;Gerhard-Herman;Circulation,2017
2. Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association;Criqui;Circulation,2021
3. Heart disease and stroke statistics-2023 update: a report from the American Heart Association;Tsao;Circulation,2023
4. Knowledge of peripheral artery disease: what do the public, healthcare practitioners, and trainees know?;Bridgwood;Vasc Med,2020
5. ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS);Aboyans;Eur Heart J,2018